Anaphore's Bowdish made president and CSO at Permeon
This article was originally published in Scrip
Permeon Biologics, a company developing intracellular biologics that target a broad spectrum of previously undruggable targets, has appointed Dr Katherine Bowdish president and chief scientific officer. Dr Bowdish also joins the board of directors. She previously co-founded drug development company Anaphore, and served as the firm's president and CEO. Dr Bowdish resigned as Anaphore's CEO in June 2011 and has since served the company as a consultant (scripintelligence.com, 21 June 2011).